Renato Zambello

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 620 citations

Hematological Malignancy, Medicine, Immunology +6

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 377 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +9

Analysis of the receptor-ligand interactions in the natural killer–mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

Daniela Pende, Grazia Maria Spaggiari, Stefania Marcenaro et al. · Blood · 2004 · 360 citations

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

Antonio Palumbo, Sara Bringhen, Anna Marina Liberati et al. · Blood · 2008 · 357 citations · Full text

The Lymphoproliferative Disease of Granular Lymphocytes: Updated Criteria for Diagnosis

Gianpietro Semenzato, Renato Zambello, Gordon Starkebaum et al. · Blood · 1997 · 348 citations